KRAS Mutation Testing in Colorectal Cancer

@article{Plesec2009KRASMT,
  title={KRAS Mutation Testing in Colorectal Cancer},
  author={Thomas P. Plesec and Jennifer Leigh Hunt},
  journal={Advances in Anatomic Pathology},
  year={2009},
  volume={16},
  pages={196-203}
}
  • T. Plesec, J. Hunt
  • Published 1 July 2009
  • Medicine, Biology
  • Advances in Anatomic Pathology
In the US, colorectal cancer is the third leading cause of cancer-related death. Approximately 20% of patients present with metastatic disease, and an additional 30% to 40% develop metastasis during the course of their disease. Patients with metastatic colon cancer have a 5-year survival rate of only 11%. Although surgery is the mainstay of treatment for early stage colon cancer, adjuvant treatment is usually used in patients advanced stage disease. In particular, epidermal growth factor… 
View on Wolters Kluwer
kras.eqascheme.org
107 Citations
Highly Influential Citations
3
Background Citations
30
Methods Citations
6
Results Citations
4

107 Citations

Citation Type

Citation Type

NCCN Updates Guidelines for Hereditary Cancer Risks
  • Medicine
    American journal of medical genetics. Part A
  • 2020
TLDR
The evidence supporting this conclusion was strong enough for the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology to recommend that KRAS variant status be determined in all patients with metastatic colorectal cancer who are candidates for anti-EGFR therapy.
KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer
TLDR
The data suggest that sampling either the primary (pre- or posttherapeutical tumor tissue) or metastatic lesion may be valid for the initial evaluation of KRAS mutation status predicting the response to anti-EGFR treatment and guiding clinical decisions.
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
TLDR
This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases.
KRAS mutation testing in metastatic colorectal cancer.
TLDR
This review provides an overview of KRAS biology and the recent advances in KRAS mutation testing and recommends that microsatellite instability, a prognostic factor, be added to the abovementioned concomitant analysis.
Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.
TLDR
In patients with advanced colorectal cancer, the addition of anti-EGFR treatment to standard chemotherapy improves PFS for those with wild-type, but not mutant KRAS status, and KRAS gene mutation testing provides a fair biomarker in predicting non-response to anti- EGFR treatment.
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
TLDR
Lung metastasis was more likely to develop during the disease course in patients whose tumours had a KRAS mutation than in those whose tumour did not have a KRas mutation, which may have an impact on decision making for surgical resection of metastatic disease.
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
TLDR
Testing the primary tumor (or whatever tissue available) is sufficient for clinical decision making on EGFR inhibitor therapy, and testing metastatic tissue in all patients along with the low incidence of discordance is concluded.
BRAF mutation testing in colorectal cancer.
TLDR
BRAF mutation testing has a role in differentiating sporadic colorectal cancer from Lynch syndrome, identifying cancers lacking BRAF mutation that are more likely to respond to epidermal growth factor receptor inhibitor therapy, and conferring worse prognosis in coloreCTal cancer that is microsatellite stable.
Development of molecular biomarkers in individualized treatment of colorectal cancer.
KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.
TLDR
KRAS status is highly homogeneous throughout primary CRC tumor areas and consistent between the primary tumor and metastatic tissue in the same patient, suggesting that testing KRAS mutations in only 1 area of the primary or metastasis tissue is suitable for predicting the response to anti-EGFR treatment and guiding clinical decisions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
TLDR
These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
TLDR
Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
TLDR
The available clinical data is reviewed, the potential implications for future drug development in colorectal cancer are discussed, and a comprehensive overview of the technical aspects of KRAS mutation testing is provided.
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
  • R. Amado, M. Wolf, +9 authors David Chang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.
TLDR
This population-based study demonstrates important relationships between Ki-ras mutations and stage, survival, tumor location, and gender.
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
TLDR
It is demonstrated for the first time that the loss of PTEN protein expression is associated with nonresponsiveness to cetuximab.
EGFR FISH in colorectal cancer: what is the current reality?
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
TLDR
The results indicate that the detection of KRAS mutations in either primary or metastatic tumors from patients with CRC is concordant and this assessment could be used to predict response to targeted therapies such as cetuximab and panitumumab.
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
  • K. Ng, A. Zhu
  • Biology, Medicine
    Critical reviews in oncology/hematology
  • 2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
TLDR
BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
...
1
2
3
4
5
...